Overall, excluding TP53 mutations, recurrent alterations in PIK3CA, PTEN and FBXW7 genes, all belonging to the PI3K/AKT/mTOR pathway, could define a potential new target for pharmacological intervention in HNSCC, as it has been suggested in other publications42. This evidence concerns the gene PTEN and head and neck squamous cell carcinoma.